Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
- PMID: 20643434
- PMCID: PMC3412428
- DOI: 10.1016/j.juro.2010.05.029
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy
Abstract
Purpose: Prostate specific antigen velocity has been proposed as a marker to aid in prostate cancer detection. We determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy.
Materials and methods: We identified 1,837 men who participated in the Göteborg or Rotterdam section of the European Randomized Screening study of Prostate Cancer and who underwent 1 or more subsequent prostate biopsies after an initial negative finding. We evaluated whether prostate specific antigen velocity improved predictive accuracy beyond that of prostate specific antigen alone.
Results: Of the 2,579 repeat biopsies 363 (14%) were positive for prostate cancer, of which 44 (1.7%) were high grade (Gleason score 7 or greater). Prostate specific antigen velocity was statistically associated with cancer risk but had low predictive accuracy (AUC 0.55, p <0.001). There was some evidence that prostate specific antigen velocity improved AUC compared to prostate specific antigen for high grade cancer. However, the small increase in risk associated with high prostate specific antigen velocity (from 1.7% to 2.8% as velocity increased from 0 to 1 ng/ml per year) had questionable clinical relevance.
Conclusions: Men with prior negative biopsy are at lower risk for prostate cancer at subsequent biopsies with high grade disease particularly rare. We found little evidence to support prostate specific antigen velocity to aid in decisions about repeat biopsy for prostate cancer.
2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Figures


Similar articles
-
A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21. BJU Int. 2012. PMID: 21939492 Clinical Trial.
-
Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.Cancer. 2007 Nov 1;110(9):1973-8. doi: 10.1002/cncr.23014. Cancer. 2007. PMID: 17886252
-
Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer.J Urol. 2000 Mar;163(3):813-8. J Urol. 2000. PMID: 10687983 Clinical Trial.
-
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.J Urol. 2014 Mar;191(3):629-37. doi: 10.1016/j.juro.2013.09.029. Epub 2013 Sep 20. J Urol. 2014. PMID: 24060641 Free PMC article.
-
Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.Rev Urol. 2014;16(3):154-6. Rev Urol. 2014. PMID: 25337050 Free PMC article. Review. No abstract available.
Cited by
-
Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review.Oncol Rev. 2020 Apr 30;14(1):449. doi: 10.4081/oncol.2020.449. eCollection 2020 Feb 18. Oncol Rev. 2020. PMID: 32399138 Free PMC article.
-
Addressing the need for repeat prostate biopsy: new technology and approaches.Nat Rev Urol. 2015 Aug;12(8):435-44. doi: 10.1038/nrurol.2015.159. Epub 2015 Jul 14. Nat Rev Urol. 2015. PMID: 26171803 Review.
-
Counterpoint: Prostate-specific antigen velocity is not of value for early detection of cancer.J Natl Compr Canc Netw. 2013 Mar 1;11(3):286-90. doi: 10.6004/jnccn.2013.0040. J Natl Compr Canc Netw. 2013. PMID: 23486455 Free PMC article.
-
Biomarkers for prostate cancer: present challenges and future opportunities.Future Sci OA. 2015 Dec 17;2(1):FSO72. doi: 10.4155/fso.15.72. eCollection 2016 Mar. Future Sci OA. 2015. PMID: 28031932 Free PMC article. Review.
-
Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.J Natl Cancer Inst Monogr. 2013;2013(46):117-23. doi: 10.1093/jncimonographs/lgt010. J Natl Cancer Inst Monogr. 2013. PMID: 23962515 Free PMC article.
References
-
- Robinson D, Sandblom G, Johansson R, et al. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer. Urology. 2008;72:903. - PubMed
-
- Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191. - PubMed
-
- Loeb S, Roehl KA, Catalona WJ, et al. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol. 2007;177:899. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical